Loading...
XETRV3V
Market cap67mUSD
Dec 23, Last price  
4.10EUR
1D
-0.49%
1Q
-10.09%
Jan 2017
-22.79%
IPO
-68.34%
Name

Vita 34 AG

Chart & Performance

D1W1MN
XETR:V3V chart
P/E
—
P/S
0.84
EPS
—
Div Yield, %
0.01%
Shrs. gr., 5y
31.21%
Rev. gr., 5y
30.44%
Revenues
77m
+11.78%
015,426,00014,957,00015,097,00016,963,00016,001,00013,603,00013,554,00013,786,00014,169,00016,290,00019,186,00020,410,00020,247,00020,070,00028,418,00068,940,00077,062,000
Net income
-2m
L-93.19%
0-1,185,000-1,712,000596,000349,0001,191,000-579,000838,0001,100,0001,979,000408,000-322,000828,0001,350,0001,449,000-3,926,000-27,385,000-1,865,000
CFO
9m
P
-341,000-1,664,000-2,939,0001,149,0001,008,000-683,0002,039,0001,775,0001,055,0002,590,0002,287,0001,530,0004,598,0006,318,0003,980,0002,727,000-4,486,0009,154,000
Dividend
Jun 05, 20190.16 EUR/sh
Earnings
Jan 29, 2025

Profile

VITA 34 AG engages in the collection, processing, and storage of stem cells from umbilical cord blood and tissue in Germany, Spain, and internationally. It also develops cell therapeutic procedures; cell and gene therapies; cryopreservation of endogenous immune cells; and CAR-T. In addition, the company manufactures advanced therapy medicinal products based on mesenchymal stem cells for experimental treatment by specialized medical institutions; preserves stem cells from perinatal tissue and adult body fat; and engages in the contract manufacturing of pharmaceutical intermediates. VITA 34 AG was founded in 1997 and is based in Leipzig, Germany.
URL
https://www.vita34.de/
IPO date
Nov 21, 2007
Employees
815
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
77,062
11.78%
68,940
142.59%
28,418
41.59%
Cost of revenue
66,648
83,670
26,175
Unusual Expense (Income)
NOPBT
10,414
(14,730)
2,243
NOPBT Margin
13.51%
7.89%
Operating Taxes
(2,309)
(908)
479
Tax Rate
21.36%
NOPAT
12,723
(13,822)
1,764
Net income
(1,865)
-93.19%
(27,385)
597.53%
(3,926)
-370.95%
Dividends
(7)
Dividend yield
Proceeds from repurchase of equity
6,997
(1,396)
BB yield
Debt
Debt current
7,808
16,126
12,614
Long-term debt
26,876
24,742
30,704
Deferred revenue
60,062
46,615
42,531
Other long-term liabilities
1,781
3,335
4,678
Net debt
17,266
23,119
8,712
Cash flow
Cash from operating activities
9,154
(4,486)
2,727
CAPEX
(3,409)
(6,431)
(2,260)
Cash from investing activities
(3,574)
(5,811)
24,871
Cash from financing activities
(5,088)
(6,273)
(4,696)
FCF
5,553
(6,438)
(21,199)
Balance
Cash
17,416
18,233
35,255
Long term investments
2
(484)
(649)
Excess cash
13,565
14,302
33,185
Stockholders' equity
25,588
(15,275)
9,783
Invested Capital
92,628
108,008
111,284
ROIC
12.68%
2.31%
ROCE
9.47%
1.77%
EV
Common stock shares outstanding
15,881
15,828
5,825
Price
Market cap
EV
EBITDA
18,976
(6,180)
6,128
EV/EBITDA
Interest
1,726
2,048
547
Interest/NOPBT
16.57%
24.39%